Skip to main navigation
Skip to search
Skip to main content
UT MD Anderson Cancer Center Home
Help & FAQ
Link opens in a new tab
Search content at UT MD Anderson Cancer Center
Home
Profiles
Research units
Equipment
Research output
Activities
Prizes
Use of amifostine in bone marrow purging
P. J. Cagnoni
, R. B. Jones
, S. I. Bearman
, M. Ross
, L. Hami
, W. A. Franklin
, R. Capizzi
, P. S. Schein
,
E. J. Shpall
Stem Cell Transplantation
Research output
:
Contribution to journal
›
Article
›
peer-review
22
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Use of amifostine in bone marrow purging'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Bone Marrow
100%
Amifostine
100%
Purging
100%
Hematopoietic Stem Cells
66%
Patients with Breast Cancer
33%
Lymphoma
16%
Malignancy
16%
Tumor Cells
16%
Engraftment
16%
Alkylating Agents
16%
Engraftment Rate
16%
Supportive Care
16%
High-dose Chemotherapy
16%
Cell Support
16%
Hodgkin Disease
16%
Randomized Clinical Trial
16%
Non-Hodgkin Lymphoma
16%
Allogeneic Bone Marrow Transplantation
16%
Colony Forming Units
16%
Granulocyte Macrophages
16%
Clonogenic Cells
16%
WR-2721
16%
Sulfhydryl Compounds
16%
Hematopoietic Grafts
16%
Medicine and Dentistry
Amifostine
100%
Bone Marrow Purging
100%
Arm
66%
Perfosfamide
50%
Breast Cancer
33%
Tumor Cell
33%
Engraftment
33%
Cancer
16%
Alkylating Antineoplastic Agent
16%
Supportive Care
16%
High Dose Chemotherapy
16%
Hematopoietic Cell
16%
Hodgkin's Lymphoma
16%
Bone Marrow Transplantation
16%
Non-Hodgkin Lymphoma
16%
Colony Forming Unit GM
16%
Thiol Derivative
16%
Randomized Clinical Trials
16%
Immunology and Microbiology
Arm
100%
Perfosfamide
75%
Engraftment
50%
Tumor Cell
50%
Hematopoietic Cell
25%
Drug Megadose
25%
Bone Marrow Transplantation
25%
Colony Forming Unit GM
25%
Preclinical Study
25%
Pretreatment
25%